Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alicia Hager Insider Profile
4 Followers
Alicia Hager, SVP & GC at OncoMed Pharma, holds 103.82K shares in Nkarta (Ticker: NKTX), holds 0.00 shares in OncoMed Pharma (Ticker: OMED).
Profitable Transactions
6 out of 8 Profitable Transactions
Average Return
+34.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
CLO
Roles that Alicia Hager holds in companies
Most Profitable Insider Trade
Stock:
OncoMed Pharma
(OMED)
(OMED)
Rating:Informative Sell
Date:Apr 26, 2018 - Apr 26, 2019
Return:+69.80%
The most profitable trade made by Alicia Hager
Alicia Hager's Trading History
OncoMed Pharma
Apr 23, 2019
―
Uninformative Sell
―
$0.00
Nkarta
Jul 18, 2024
CLO
Uninformative Sell
27.17K
$246.05K
List of latest transactions for each holding click on a transaction to see Alicia Hager's performance on stock
You May Also Like
Alicia Hager insider profile FAQ
What is the percentage of profitable transactions made by Alicia Hager?
The percentage of profitable transactions made by Alicia Hager is 75%.
What is the average return per transaction made by Alicia Hager?
The average return per transaction made by Alicia Hager is 34.60%.
What stocks does Alicia Hager hold?
Alicia Hager holds: OMED, NKTX stocks.
What was Alicia Hager’s latest transaction?
Alicia Hager latest transaction was an Uninformative Sell of $27.17K.
What was Alicia Hager's most profitable transaction?
Alicia Hager’s most profitable transaction was an Informative Sell of OMED stock on April 26, 2018. The return on the trade was 69.80%.
What is Alicia Hager's role in OncoMed Pharma?
Alicia Hager's role in OncoMed Pharma is SVP & GC.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.